Novo Nordisk
Novo goes after pharmacies compounding semaglutide
Danish pharma giant declares some compounded versions up to one-third impure The manufacturer of diabetes and weight-loss drugs Ozempic and Wegovy has taken legal action against two compounding pharmacies, accusing …
‘King Kong’ drug Mounjaro now in short supply into 2024
Recently launched diabetes med with weight loss hype another victim of ‘larger than expected demand’ Mounjaro, the hotly anticipated competitor to social media-hyped diabetes and de facto weight loss drug …
Another diabetes drug scarce until end 2024
Eli Lilly’s Trulicity had been been ‘go-to’ replacement for in-demand Ozempic Trulicity, the type-2 diabetes preparation which had been a regular stop-gap option when the much-hyped Ozempic was in short …
Ozempic fattens Commonwealth coffers – slightly
Ozempic manufacturer, Novo Nordisk’s tax bill more than doubled in the 2021/22 financial year, data from the Australian Taxation Office (ATO) reveals Surging demand for Novo Nordisk’s diabetes medication, Ozempic …
No new Ozempic scripts: TGA
Prescribers urged not to start new patients on Ozempic, as Novo Nordisk warns of supply shortages throughout 2024 Ozempic supplier, Novo Nordisk, is warning that supply of the diabetes medication …
Ozempic competitor to launch in spite of PBS knockback
Eli Lilly’s Mounjaro will be on the private scrip market by the end of September Revolutionary new type 2 diabetes drug Mounjaro – which is almost better known for producing …
Ozempic diabetes competitor gets PBS knockback
Eli Lilly’s Mounjaro would need “substantial price reduction”, says PBAC Mounjaro, the type-2 diabetes medication that the New York Times recently predicted “’could overshadow Ozempic” has been refused funding via …
Somatropin stocks hit on two fronts
One version of the synthetic growth hormone in short supply while another is discontinued The somatropin products marketed as Norditropin FlexPro 5mg, 10mg and 15mg will be in shortage until …
Ozempic shortage pain to continue until year’s end
TGA underscores ‘limited availability’ means drug should still only be prescribed for type-2 diabetes There will be continued “limited availability” of diabetes drug Ozempic until 31 December 2023 due to …
Semaglutide cancer and depression risks investigation
Concerns Ozempic ingredient may be related to thyroid cancer and suicide ideation draws attention of EMA Semaglutide, the active ingredient in hyped diabetes and weight loss drug, Ozempic and others, …
Oral semaglutide as effective as injectable
Ozempic/Wegovy sponsor trumpets results of Phase III clinical trial as its halts US ads A trial of an oral version of Novo Nordisk’s obesity and diabetes medication semaglutide, the active …
No Ozempic until end of March 2023: TGA
TGA says the diabetes drug will be unavailable from mid-November until end of March next year – but drug company’s message is not quite so bleak The lingering months-long shortage …